Patents/Inventors

Thomas John Van Blarcom

Oakland, CAUS16 patents

16 Patents

US126066232026
DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
PFIZER Inc.
0 cites
US125772832026
Knockdown or Knockout of One or More of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to Mitigate T Cell Recognition of Allogeneic Cell Products
Allogene Therapeutics, Inc.
0 cites
US125772902026
Fasl Expression and Fasr Gene Knockout to Protect Therapeutic Cells from Allogeneic Rejection and Activation-induced Cell Death
Allogene Therapeutics, Inc.
0 cites
US125288562026
Chimeric Cytokine Receptors Comprising TGF Β Binding Domains
Allogene Therapeutics, Inc.
0 cites
US124043152025
Protease-activating Cd45-gate CAR
Pfizer Inc.
0 cites
US122153472025
Chimeric Antigen Receptors with Enhanced Signaling and Activities and Uses Thereof
Allogene Therapeutics, Inc.
0 cites
US121631692024
Inducible Chimeric Cytokine Receptors
Allogene Therapeutics, Inc.
0 cites
US121041882024
Modified Caspase-9 Polypeptides and Methods of Use Thereof
Allogene Therapeutics, Inc.
0 cites
US120436552024
Constitutively Active Chimeric Cytokine Receptors
Allogene Therapeutics, Inc.
0 cites
US120362432024
BCMA CAR-T Cells with Enhanced Activities
Allogene Therapeutics, Inc.
0 cites
US119876342024
Antibodies Specific for CD70 and Their Uses
PFIZER Inc.
0 cites
US119127762024
Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
PFIZER Inc.
0 cites
US118144352023
Therapeutic Antibodies and Their Uses
PFIZER Inc.
0 cites
US117865532023
Chimeric Cytokine Receptors Bearing a PD-1 Ectodomain
ALLOGENE THERAPEUCTICS, Inc.
0 cites
US117024742023
Antibodies Specific for CD47, PD-L1, and Uses Thereof
Pfizer Inc.
0 cites
US116739532023
DLL3 Targeting Chimeric Antigen Receptors and Binding Agents
PFIZER Inc.
0 cites